VolitionRX (VNRX)

• Market cap: $47M
• 1 day: -2.45%
• 5 days: -0.31%
• 1 month: -13.09%
• 3 months: -24.13%
• 6 months: -34.61%
• Year to date: -24.13%
• 1 year: -20.33%
• 5 years: -87.22%
• 10 years: -87.49%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Employees: 85

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

27% more funds holding

Funds holding: 22 [Q3] → 28 (+6) [Q4]

6% more capital invested

Capital invested by funds: $10.5M [Q3] → $11.2M (+$680K) [Q4]

0.44% more ownership

Funds ownership: 19.03% [Q3] → 19.48% (+0.44%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2.50 423% upside
• Avg. target: $3.75 685% upside
• High target: $5 946% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 28% 1-year accuracy 48 / 172 met price target	423% upside $2.50	Buy Reiterated	11 Apr 2025
D. Boral Capital Jason Kolbert 19% 1-year accuracy 67 / 357 met price target	946% upside $5	Buy Maintained	1 Apr 2025